Literature DB >> 29217749

Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo.

Katja Giersch1, Oliver D Bhadra1, Maura Dandri1,2, Marc Lütgehetmann3, Tassilo Volz1, Lena Allweiss1, Kristoffer Riecken4, Boris Fehse4, Ansgar W Lohse1,2, Joerg Petersen5, Camille Sureau6, Stephan Urban2,7.   

Abstract

OBJECTIVE: Hepatitis delta virus (HDV) was shown to persist for weeks in the absence of HBV and for months after liver transplantation, demonstrating the ability of HDV to persevere in quiescent hepatocytes. The aim of the study was to evaluate the impact of cell proliferation on HDV persistence in vitro and in vivo.
DESIGN: Genetically labelled human sodium taurocholate cotransporting polypeptide (hNTCP)-transduced human hepatoma(HepG2) cells were infected with HBV/HDV and passaged every 7 days for 100 days in the presence of the entry inhibitor Myrcludex-B. In vivo, cell proliferation was triggered by transplanting primary human hepatocytes (PHHs) isolated from HBV/HDV-infected humanised mice into naïve recipients. Virological parameters were measured by quantitative real time polymerase chain reaction (qRT-PCR). Hepatitis delta antigen (HDAg), hepatitis B core antigen (HBcAg) and cell proliferation were determined by immunofluorescence.
RESULTS: Despite 15 in vitro cell passages and block of viral spreading by Myrcludex-B, clonal cell expansion permitted amplification of HDV infection. In vivo, expansion of PHHs isolated from HBV/HDV-infected humanised mice was confirmed 3 days, 2, 4 and 8 weeks after transplantation. While HBV markers rapidly dropped in proliferating PHHs, HDAg-positive hepatocytes were observed among dividing cells at all time points. Notably, HDAg-positive cells appeared in clusters, indicating that HDV was transmitted to daughter cells during liver regeneration even in the absence of de novo infection.
CONCLUSION: This study demonstrates that HDV persists during liver regeneration by transmitting HDV RNA to dividing cells even in the absence of HBV coinfection. The strong persistence capacities of HDV may also explain why HDV clearance is difficult to achieve in HBV/HDV chronically infected patients. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  cell proliferation; hepatitis d; hepatocyte

Mesh:

Substances:

Year:  2017        PMID: 29217749     DOI: 10.1136/gutjnl-2017-314713

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  21 in total

Review 1.  HBV/HDV Coinfection: A Challenge for Therapeutics.

Authors:  Christopher Koh; Ben L Da; Jeffrey S Glenn
Journal:  Clin Liver Dis       Date:  2019-05-24       Impact factor: 6.126

2.  Hepatitis D infection: from initial discovery to current investigational therapies.

Authors:  Ben L Da; Theo Heller; Christopher Koh
Journal:  Gastroenterol Rep (Oxf)       Date:  2019-06-23

3.  Mathematical modeling suggests that entry-inhibitor bulevirtide may interfere with hepatitis D virus clearance from circulation.

Authors:  Louis Shekhtman; Scott J Cotler; Alexander Ploss; Harel Dahari
Journal:  J Hepatol       Date:  2022-01-05       Impact factor: 30.083

Review 4.  A review on hepatitis D: From virology to new therapies.

Authors:  Nathalie Mentha; Sophie Clément; Francesco Negro; Dulce Alfaiate
Journal:  J Adv Res       Date:  2019-03-29       Impact factor: 10.479

5.  Recapitulation of HDV infection in a fully permissive hepatoma cell line allows efficient drug evaluation.

Authors:  Florian A Lempp; Franziska Schlund; Lisa Rieble; Lea Nussbaum; Corinna Link; Zhenfeng Zhang; Yi Ni; Stephan Urban
Journal:  Nat Commun       Date:  2019-05-22       Impact factor: 14.919

6.  A dual role for SAMHD1 in regulating HBV cccDNA and RT-dependent particle genesis.

Authors:  Peter Ac Wing; Tamara Davenne; Jochen Wettengel; Alvina G Lai; Xiaodong Zhuang; Anindita Chakraborty; Valentina D'Arienzo; Catharina Kramer; Chunkyu Ko; James M Harris; Sabrina Schreiner; Martin Higgs; Stephanie Roessler; Joanna L Parish; Ulrike Protzer; Peter Balfe; Jan Rehwinkel; Jane A McKeating
Journal:  Life Sci Alliance       Date:  2019-03-27

Review 7.  The oncogenic role of hepatitis delta virus in hepatocellular carcinoma.

Authors:  Marc Puigvehí; Carlos Moctezuma-Velázquez; Augusto Villanueva; Josep M Llovet
Journal:  JHEP Rep       Date:  2019-05-16

8.  Strong Replication Interference Between Hepatitis Delta Viruses in Human Liver Chimeric Mice.

Authors:  Katja Giersch; Lennart Hermanussen; Tassilo Volz; Annika Volmari; Lena Allweiss; Camille Sureau; John Casey; Jiabin Huang; Nicole Fischer; Marc Lütgehetmann; Maura Dandri
Journal:  Front Microbiol       Date:  2021-07-08       Impact factor: 5.640

9.  Elevated NTCP expression by an iPSC-derived human hepatocyte maintenance medium enhances HBV infection in NTCP-reconstituted HepG2 cells.

Authors:  Xinlei Li; Zhaohui Xu; Bidisha Mitra; Minghang Wang; Haitao Guo; Zongdi Feng
Journal:  Cell Biosci       Date:  2021-07-05       Impact factor: 7.133

Review 10.  Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease.

Authors:  Stephan Urban; Christoph Neumann-Haefelin; Pietro Lampertico
Journal:  Gut       Date:  2021-06-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.